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Multiple sclerosis (MS) is an inflammatory disease affecting the brain and spinal cord 
and it is the main cause of neurological disability among young adults. Recombinant 
interferon beta (IFNβ) and natalizumab are commonly used disease-modifying drugs 
that reduce disease severity. Even though these treatments show beneficial clinical 
effects they are associated with the development of anti-drug antibodies (ADAs), which 
at high titer levels reduce drug efficacy. Although ADAs are known to adversely affect 
the clinical effect of the treatment on a group level, the treatment response in individual 
patients is less characterized. In addition, it is unknown why only a subgroup of treated 
MS patients develops ADAs. The objective of this thesis was to identify biologically 
relevant ADA titer cut-points that can be used to predict treatment response and 
persistence of ADAs in individual patients, and to investigate if genetic and 
immunological factors influence the development of ADAs in MS patients. 
 
MS patients analyzed for the presence of ADAs against IFNβ or natalizumab in the 
routine NAb laboratory at Karolinska Institutet were included in this project. In 
Sweden, NAb monitoring became clinical practice in 2003 and during 2003-2004 the 
overall seroprevalence of neutralizing antibodies (NAbs) against IFNβ was 32%. When 
the NAb seroprevalence was analyzed five years later, in 2009-2010, the overall 
frequency of NAb-positive patients had decreased significantly to 19%. Importantly, 
the greatest reduction was observed in patients with high NAb titers (study I). By 
correlating the in vivo IFNβ bioactivity with patients’ NAb titers we identified that a 
NAb titer of 150 TRU/ml is a biologically functional cut-point for treatment response, 
since titers above 150 TRU/ml completely block IFNβ bioactivity (study II). 
Furthermore, characterization of ADA responses in natalizumab-treated patients 
revealed that the level of total anti-natalizumab antibodies in a first positive sample can 
be used to predict patients at risk of becoming persistently antibody positive (study V).  
 
It is known that factors such as protein modifications and/or impurities impact the 
immunogenicity of IFNβ, which can explain the variation in NAb positivity between 
IFNβ preparations. In addition, since only a subgroup of IFNβ-treated patients develops 
NAbs, patient-related factors are likely to influence the immunogenicity of IFNβ. In 
study III, we hypothesized that MS patients with and without intrathecal production of 
oligoclonal IgG bands (OCB) have different propensities to induce humoral immune 
responses. The presence of OCB was found to be associated with NAb development, 
and this risk was confined to NAbs against IFNβ-1a. From these results we proposed 
that MS patients with and without OCB differ immunologically, potentially influenced 
by distinct human leukocyte antigen (HLA) alleles. The role of HLA in the 
immunogenicity of IFNβ was further investigated in study IV, in which we found that 
HLA-DRB1*15 carriage was associated with increased risk of developing NAbs. 
Stratification on type of IFNβ preparation showed that HLA-DRB1*15 increased the 
risk of NAbs against IFNβ-1a, while HLA-DRB1*04 increased the risk of NAbs against 
IFNβ-1b, indicating that there is an IFNβ preparation-specific genetically determined 
risk to develop NAbs. 
 
Overall, these results can be used to assist when making decisions about whether 
treatment should be discontinued or not. In addition, the identification of factors 
contributing to the immunogenicity of protein therapeutics can increase our 
understanding of the immunological mechanisms leading to ADA responses, possibly 
resulting in less immunogenic drugs in the future. 
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1 INTRODUCTION 
1.1 MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS) that affects millions of people worldwide and it is the main cause of 
neurological disability among young adults [1]. In Sweden, the disease affects 189 per 
100,000 individuals, and women are more than twice as often affected [2].  
 
The disease is characterized by development of inflammatory demyelinating white 
matter lesions, plaques, in the brain and spinal cord. In lesions where myelin and the 
myelin-producing oligodendrocytes are permanently lost, astrocytes form glial scars 
(sclerae), and as the name multiple sclerosis implies, these scars form at multiple sites 
in the CNS. Demyelination continues in both white and grey matter, and over time both 
axons and neurons are injured and lost. In affected patients the chronic inflammation 
and neurodegeneration will in time lead to gradual accumulation of disability [3], 
which impacts on the patients’ health-related quality of life [1]. Although MS is 
usually not the direct cause of death, patients have a slightly reduced life expectancy 
compared to the general healthy population [4]. 
 
Disease symptoms usually start between the ages of 20 and 40, but subclinical disease 
activity possibly begins before clinical presentation. Depending on where the lesions 
occur in the CNS, patients may suffer loss of neurological functions in motor, sensory, 
visual and autonomic systems. More specific signs and symptoms that frequently occur 
at disease onset are, for example, weakness in arms and legs, impaired movement, 
dizziness, inflammation of the optic nerve, and double or loss of vision [3].  
 
Depending on the clinical picture and disease course, MS is classified into relapsing-
remitting (RR), primary progressive (PP) and secondary progressive (SP) disease. 
About 80-90% of patients receive the diagnosis relapsing-remitting disease, which is 
characterized by acute attacks of disease symptoms (relapses) followed by periods of 
full or partial recovery (remission) from symptoms. In 80-90% of the patients with 
RRMS, the frequency of inflammatory driven relapses decrease over time, and within 
10 to 20 years from onset the disease evolves into a secondary-progressive phase with 
gradual accumulation of disability. Primary-progressive disease affects only 10-15% of 
patients with MS, and is characterized by less pronounced inflammation and with 
accumulation of disability from disease onset [3,5,6]. 
 
For a diagnosis of MS to be made, according to the McDonald criteria, there needs to 
be evidence of at least two demyelinating events that are separated in time and space. 
This is done primarily by clinical history and neurological examination, but paraclinical 
investigations can be made to support the diagnosis or disease course. These tests 
include examination of lesion burden and axonal loss using magnetic resonance 
imaging (MRI), and detection of intrathecal synthesis of oligoclonal immunoglobulin 
(Ig) G by cerebrospinal fluid (CSF) analysis [7,8]. The presence of oligoclonal IgG 
bands (OCBs) or elevated IgG levels in CSF compared to paired serum or plasma 




1.1.1 Pathogenesis and disease mechanisms 
The disease is believed to be initiated when CD4+ T cells, by unknown mechanisms, 
are activated in the periphery and enter the inflamed CNS by transmigration across the 
blood-brain barrier (BBB). Within the CNS, the activated T cells recognize their 
specific target antigens (e.g. myelin-derived peptides) presented by antigen-presenting 
cells (APCs).This leads to increased production of pro-inflammatory factors, e.g. 
cytokines and chemokines, by activated CD4+ effector T cells, infiltrating 
macrophages, and CNS resident microglia and astrocytes, which attract additional 
immune cell subsets (cytotoxic CD8+ T cells, B cells and innate immune cells) into the 
CNS (reviewed in [10]). The toxic environment that is produced by soluble 
inflammatory mediators, together with targeted myelin destruction and killing of 
myelin-producing oligodendrocytes by CD8+ effector T cells and antibody-mediated 
mechanisms, result in focal demyelination and axonal loss (reviewed in [11,12]).  
 
T cells (CD4+ and CD8+) and macrophages (antigen-presenting cells, APCs) are the 
most abundant immune cells present in MS lesions, while B cells and antibody-
producing plasma cells are found at lower frequencies [13]. In addition, studies on 
animals with experimental autoimmune encephalomyelitis (EAE), a model for MS, 
have shown that myelin-reactive CD4+ T cells are necessary for transfer of disease 
from affected to non-affected animals [14]. These findings have led to the assumption 
that MS is a T-cell mediated autoimmune disease.  
 
B cells and antibodies were previously not considered to play key roles in the disease 
process. Today it is evident that both components are involved in mechanisms 
contributing to disease. The detection of clonal expansion and somatic mutation of B 
cells in the CNS and CSF [15-17], which participate in the intrathecal synthesis of IgG 
and OCBs [18-20], indicates that these responses are T cell-dependent and antigen 
driven. In addition, clonal B-cell expansion is detected in a majority of patients with a 
first clinical episode suggestive of MS, or clinically isolated syndrome (CIS). These 
clonal B cells seems to develop before detectable OCBs and MRI lesions, suggesting 
that antigen-specific B-cells are involved in the early phase of disease [16]. 
Furthermore, treatment of MS patients with a B-cell depleting monoclonal anti-CD20 
antibody, rituximab, rapidly reduced inflammatory lesions on MRI [21], suggesting that 
B cells also are involved in formation of acute lesions.  
 
Although B-cell mediated humoral immunity is important for disease, this does not 
seem to be the case in all patients with MS. The fact that intrathecal OCBs, a typical 
finding in MS, are undetectable in 5% to 10% of patients with MS indicates that this 
group differ immunologically from patients with OCBs. Indeed, these patients make up 
two immunogenetically different subgroups of MS as they have been found associated 
with distinct human leukocyte antigen (HLA) class II alleles, HLA-DRB1*15:01 with 
OCB-positive MS and HLA-DRB1*04:04/04:05 with OCB-negative MS [22-24]. 
Several studies have also shown that OCB-negative MS is associated with better 
clinical outcome in terms of lower relapse rate, less disability and slower disease 
progression [22,25-28], whereas others have found no difference [23,29,30] or even 
opposite results [31]. Findings also suggest that patients with OCB-negative MS 
respond better to interferon beta therapy than those with OCB-positive MS [32]. 
Altogether, this might indicate that these groups differ in respect to humoral immunity 
and possibly also in disease mechanism.   
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1.1.2 Factors influencing disease 
1.1.2.1 Genetic factors 
Although the etiology of MS is unknown, both genetic and environmental factors have 
been identified to influence susceptibility to disease. Among the genetic factors 
identified so far, the most important risk factors are located to the HLA region. The 
strongest associated gene, the HLA class II allele HLA-DRB1*15:01 [33], has been 
reported to increase the risk for MS about 3-fold, whereas a protective effect has been 
shown for the HLA class I allele, HLA-A*02 [33-35]. Given that HLA plays a central 
role in antigen presentation to T cells, and that most other associated genes also 
seems to be important for the immune system [33,36], it is likely that both antigen 
presentation and immune dysregulation are important mechanisms in the 
development of MS. However, the genetic susceptibility can only partially explain 
why some individuals become affected, since the concordance rate in monozygotic 
twins has been reported to be around 24-26% while it is around 2-3% for dizygotic 
twins and non-twin siblings [37,38]. This indicates that additional environmental 
factors are needed to trigger the disease in genetically susceptible individuals. 
 
1.1.2.2 Environmental and life-style factors 
1.1.2.2.1 Virus infections 
Based on results from both epidemiological studies and studies on other demyelinating 
CNS diseases, virus infections have been extensively investigated as possible triggers 
of MS (reviewed in [39]). Two candidate viruses suggested to play a role in MS are 
Epstein-Barr virus (EBV) and human herpes virus (HHV)-6. Epidemiological studies 
have reported an increased risk for MS in EBV-infected individuals, especially if 
primary infection occur in adulthood and results in infectious mononucleosis [40-42]. 
For HHV-6, serological studies have reported higher prevalence of anti-HHV-6 IgM 
and IgG antibodies in MS patients compared to controls [43,44]. Studies have also 
reported that viral DNA or viral products from both EBV [45,46] and HHV-6 [47,48] 
are present in brain and active lesions of MS patients, but not in controls. Furthermore, 
immunological studies on CSF in MS patients have shown that fractions of OCB are 
reactive against specific antigens from both EBV and HHV-6 [49-51]. Although other 
studies have reported contradictory results, viruses may still play a role in the disease. 
 
1.1.2.2.2 Sunlight exposure and vitamin D 
Observations of higher MS prevalence in areas closer to the north and south poles 
suggest that low sunlight exposure and/or low vitamin D levels increase disease 
susceptibility [52]. This is supported by the fact that both factors are recognized to have 




Several epidemiological studies have shown that tobacco smoking significantly 
increases the risk of MS [54-56]. The exact mechanisms behind this increased risk in 
smokers are not known, but some substances in tobacco smoke have modulatory effects 
on immune cell function and can impair both cell-mediated and humoral immunity 




1.2 TREATMENTS IN MULTIPLE SCLEROSIS 
Since the cause of MS is unknown there is no cure for the disease. However, there are a 
number of disease-modifying treatments that reduce disease symptoms as well as 
disease severity and disability accumulation over time. In patients with severe and 
rapidly progressing MS autologous hematopoietic stem cell transplantation therapy is 
now being used. Although this therapy has shown promising results in MS patients it is 
also associated with an increased risk of mortality [59,60]. Thus, transplantation 
therapy is carried out only in patients where other therapies have failed. For the large 
group of MS patients with a relatively better disease course, different types of 
immunomodulatory treatments are used instead, which have shown to improve the 
disease to some extent, or even give very good results. Two of the immunomodulatory 
treatments most commonly used today are interferon beta and natalizumab. 
 
1.2.1 Interferon beta treatment  
1.2.1.1 Type I interferons 
Interferon beta (IFNβ) is a cytokine that belongs to the IFN family, which includes 
three groups of related cytokines: type I IFNs, type II IFN and the recently described 
type III IFNs. In humans, the type I IFN group includes IFNα, IFNβ, IFNε, IFNκ and 
IFNω. In comparison, IFNγ is the only type II IFN and the type III IFN group consists 
of three IFNλ molecules. These types of IFNs bind to distinct receptor complexes and 
thereby they have different biological functions than the cytokines belonging to type I 
IFNs (reviewed in [61]).  
 
Type I IFNs are widely expressed in our bodies. These cytokines are a part of the innate 
immune response and are important in the first-line defense against viral infections by 
directly inhibiting viral replication in infected cells [62]. Of the type I IFNs, IFNα and 
IFNβ are the most studied. In response to viruses and viral components, e.g. double 
stranded RNA, high levels of IFNα and IFNβ are produced by plasmacytoid dendritic 
cells (DCs) and fibroblasts respectively (reviewed in [61]). However, all nucleated cells 
can produce type I IFNs if they become infected with virus.   
 
The type I IFNs share sequence similarities and they all signal through the same type I 
IFN receptor, consisting of the two subunits IFNAR1 and IFNAR2. The IFNAR1/2 
complex is expressed on the surface of most cell types, which account for their 
important role in innate immunity. Although all type I IFNs signal through the same 
receptor complex they interact with the receptor differently, which account for their 
specific biological functions (reviewed in [61,63]).  
 
The intracellular part of each receptor subunit interacts with a specific molecule of the 
Janus activated kinase (JAK) family: IFNAR1 with the JAK tyrosine kinase 2 (TYK2) 
and IFNAR2 with JAK1. When type I IFNs, e.g. IFNβ, bind to the extracellular domain 
of the receptor the IFNAR1 and IFNAR2 subunits dimerize, which results in 
autophosphorylation and activation of TYK2 and JAK1. The activation of JAKs result 
in subsequent phosphorylation and dimerization of STAT1 and STAT2 (signal 
transducer and activator of transcription 1/2); this STAT dimer then associates with 
IRF9 (IFN-regulatory factor 9) which leads to the formation of the ISGF3 (IFN-
stimulated gene factor 3) complex. The ISGF3-trimer complex is then able to 
translocate to the cell nucleus where it binds to specific promoter elements in the DNA, 
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so called ISREs (IFN-stimulated response elements), and start the transcription of 
interferon-stimulated genes (ISGs) (reviewed in [61,63]).     
 
Type I IFN signaling alters the expression of hundreds of genes which encode for 
products that for example have antiviral (myxovirus resistance proteins; MxA and 
MxB), anti-proliferative/pro-apoptotic and immunomodulatory effects. These 
biological activities of the type I IFNs has made them useful as treatments for several 
disorders. Today, IFNα is used for treatment of different cancers and chronic viral 
infections, whereas IFNβ is used as a treatment in MS (reviewed in [61]).  
 
1.2.1.2 Recombinant interferon beta 
1.2.1.2.1 Product properties 
Two types of recombinant IFNβ products are used for treatment of MS, IFNβ-1a and 
IFNβ-1b. The IFNβ-1a preparations are injected either at 30 µg intramuscularly (i.m.) 
once a week or at 22 µg and 44 µg subcutaneously (s.c.) three times a week, and the 
IFNβ-1b preparation is injected at 250 µg s.c. every other day. Recombinant IFNβ-1a is 
expressed in a Chinese hamster ovarian (CHO) cell line and is identical to human IFNβ, 
both in primary sequence (166 amino acids) and in structure. Recombinant IFNβ-1b is 
expressed in a prokaryotic system using Escherichia coli, and therefore it lacks the N-
terminal methionine (Met1) and the asparagine-linked glycosylation at position 80 
(Asn80). To improve the quality of the protein, IFNβ-1b also carries a cysteine-to-serine 
substitution at position 17 (Cys17Ser). Thus, IFNβ-1b differs both in amino acid 
sequence (165 amino acids) and in carbohydrate content compared to human IFNβ and 
recombinant IFNβ-1a. Despite these structural differences both recombinant IFNβ 
products have similar biological activities [64]. However, when comparing these two 
products in bioactivity assays, the IFNβ-1a has been shown to be more potent than 
IFNβ-1b [65]. The lower potency of IFNβ-1b is likely to be a result of the lack of 
glycosylation, since this post-translational modification is considered to stabilize the 
protein structure. The lack of glycosylation also makes IFNβ-1b less hydrophilic in 
solution, making it more prone to aggregate compared to IFNβ-1a. As a result of the 
lower potency of IFNβ-1b, it is given at a higher weekly dose compared to the IFNβ-1a 
preparations. The weekly dose of each preparation is: 30 µg for i.m. IFNβ-1a, 66 µg or 
132 µg for s.c. IFNβ-1a, and 875 µg for IFNβ-1b.   
 
1.2.1.2.2 Therapeutic efficacy   
Since IFNβ is a pleiotropic cytokine with a complex mechanism of action the exact 
mechanism(s) behind its beneficial effect in the treatment of MS is still not completely 
elucidated. Although viral infections might play a role in MS and IFNβ has potent 
antiviral functions it is the immunomodulatory properties of IFNβ that are considered 
to be the most relevant for its therapeutic effect in MS. IFNβ has both pro- and anti-
inflammatory properties. In diseases like systemic lupus erythematosus, rheumatoid 
arthritis, psoriasis, and neromyelitis optica the pro-inflammatory effects of IFNβ has 
been shown to augment the autoimmune inflammatory responses. In contrast, IFNβ 
seems to exert anti-inflammatory effects in MS (reviewed in [66,67]).  
 
In MS, IFNβ can prevent breakdown of the BBB, which is an early event in the disease 
process that promotes lesion formation, by reducing expression of proteolytic enzymes 
like matrix metalloproteinase-9 (MMP-9) and increasing expression of the MMP-9 
inhibitor TIMP-1 (tissue inhibitors of metalloproteinase-1) [68-70]. IFNβ treatment 
has also been reported to down-regulate cell surface expression of the α-4 integrin, 
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part of the very late antigen-4 (VLA-4), on T cells (CD4+ and CD8+) [71,72], and to 
increase the expression of soluble vascular cell adhesion molecule-1 (VCAM-1) on 
endothelial cells [73]. Thus, the strengthened integrity of the BBB and the reduced 
capacity of T cells to cross the BBB may be two of several mechanisms by which 
IFNβ induces its therapeutic effect in MS.  
 
IFNβ also seems to shift the cytokine profile from a pro-inflammatory to an anti-
inflammatory state, by reducing the production of IL-12 and IFNγ while increasing 
IL-10 production [74-76]. In addition, recent findings suggest that IFNβ suppress the 
differentiation of IL-17-producing T helper 17 cells, which are important in 
autoimmune responses [77], and this effect seems to be mediated by IFNβ-induced 
production of IL-27 [78]. Furthermore, IFNβ has been suggested to have 
neuroprotective effects by promoting astrocytes to produce nerve growth factor or by 
neuronal protection [79,80].    
 
1.2.1.2.3 Responders and non-responders to interferon beta treatment 
Although IFNβ significantly reduce disease activity and severity, it is only partially 
effective and around 20% of treated patients show no or poor response to IFNβ. 
Pharmacogenomic studies have identified genetic variations, i.e. single nucleotide 
polymorphisms (SNPs), associated with genes for IFNAR2, ion channels and signal 
transduction pathways that differed between responders and non-responders to 
treatment [81,82]. Results from genome-wide expression studies also suggest that 
differential expression of IFNβ-inducible genes is correlated with response to IFNβ 
treatment [83,84].  
 
1.2.2 Natalizumab 
Natalizumab is approved for the treatment of RRMS and has proven to be very efficient 
to reduce relapse rates, lesion formation and risk of disability progression, both in 
clinical trials [85,86] and in post-marketing settings [87-89]. Today, in Sweden, 
natalizumab is used as a second line treatment in RRMS patients who do not tolerate or 
respond well to first line treatments such as IFNβ, but it can also be used as a first line 
treatment in MS patients with an aggressive disease onset. 
 
Natalizumab is a recombinant monoclonal antibody that binds to the α4 subunit of the 
α4β1 integrin (VLA-4) and the α4β7 integrin (reviewed in [90]). Based on the results 
from studies in the EAE model, it was shown that antibodies which blocked the α4β1 
integrin inhibited the binding of T cells and monocytes to the inflamed BBB. 
Furthermore, antibodies against α4-integrin prevented the development of EAE by 
reducing infiltration of immune cells in the CNS [91]. The main ligand for VLA-4 is 
the vascular cell adhesion molecule (VCAM)-1, which is upregulated on endothelial 
cells during inflammation. Natalizumab acts by blocking this interaction which 
prevents T cells from crossing the BBB to enter the CNS, reducing inflammatory 
response as well as subsequent reduction in myelin and axonal damage (reviewed in 
[92]).  
 
Natalizumab was originally a mouse monoclonal antibody, but it was later humanized 
by grafting the complementarity-determining regions of the murine antibody onto a 
human IgG4 antibody backbone [93]. Natalizumab has been found to be generally well 
tolerated [85-87], but despite its similarity with a human IgG4 antibody treatment with 
natalizumab has been shown to induce the development of ADAs that can reduce the 
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therapeutic efficacy [85,86]. Thus, patients who develop persistent ADA responses 
should discontinue treatment.  
 
1.3 ANTI-DRUG ANTIBODY DEVELOPMENT 
Both IFNβ and natalizumab are examples of the increasing numbers of biological 
protein therapeutics that have been developed to treat disease, also known as 
biopharmaceuticals (BPs). Since BPs are produced to be similar or almost identical to 
the human homologous protein, these drugs are expected to be well tolerated by the 
immune system. Despite these similarities, BPs can still be considered as foreign by the 
immune system, subsequently leading to breakage of tolerance and development of 
anti-drug antibodies (ADAs). Thus, development of ADAs is an unwanted 
immunological response to BPs and it is associated with a decrease or complete loss of 
therapeutic efficacy. In addition, ADAs can cross-react with the endogenous human 
protein, which at worst can result in severe or life-threatening side effects. An example 
was the development of ADAs against recombinant erythropoietin that caused pure cell 
aplasia in patients treated for chronic renal failure, since the ADAs neutralized the 
effect of the endogenous protein as well [94]. 
 
1.3.1 Immunological mechanisms behind antibody development 
Antibodies against BPs can be divided into two subtypes: binding antibodies (BAbs) 
and neutralizing antibodies (NAbs). BAbs are considered to have little or no effect on 
the pharmacological response to BPs, whereas NAbs interfere with the bioactivity of 
BPs and reduce the treatment effect. NAbs are typically of the IgG subclass, indicating 
that humoral immune responses to BPs are mainly induced by activation of B cells with 
help from T cells (CD4+ T helper cells), i.e. classical immune response.  
 
In a T-cell dependent B-cell response, the antigen (e.g. BP) is taken up and processed 
by professional APCs such as DCs. Processed antigen peptides are presented on the cell 
surface by HLA class II molecules to antigen-specific T cells that then are activated. At 
the same time, the antigen is taken up and processed into peptides by B cells that 
express antigen-specific B-cell receptors (BCRs, IgM and IgD), resulting in B-cell 
activation (signal 1) and presentation of the antigen by HLA class II molecules 
expressed on the B-cell surface. The B cell receives additional signals by interaction 
with activated antigen-specific T cells which release cytokines (signal 2), as well as 
through Toll-like receptors (TLRs) that bind to structures on the protein (signal 3). 
These signals complete the maturation process of the B cell, which undergoes antibody 
class-switching and somatic hypermutation with the subsequent production of high-
affinity antibodies that can neutralize the antigen (e.g. BP). The T-cell dependent 
activation also promotes B cells to differentiate into memory cells and long-lived 
plasma cells (reviewed in [95,96]).  
 
Even though recombinant human proteins should not be regarded as foreign by the 
immune system, factors like protein modifications (e.g. sequence modification, 
presence/absence of post-translational modifications) and repetitive parenteral route of 
administration may render them immunogenic. ADA responses to BPs could also be 
induced without the help from T cells, i.e. T-cell independent responses. In this 
scenario, activation of the B cell occurs via TLR stimulation by so called “danger 
signals” that can override the additional need of T-cell help (reviewed in [96,97]). A 
potential trigger of danger signals is the tissue damage caused by repetitive injections of 
BPs. In addition, protein aggregates present in the drug formulation can cross-link 
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BCRs and activate B-cell proliferation independent of T-cell help. Moreover, 
aggregates are efficiently taken up by APCs which can enhance T-cell dependent 
immune responses (reviewed in [97]). 
 
In addition to these extrinsic factors, immunogenicity of BPs is also influenced by 
patient-related factors such as genetic variations or deficiencies, and immunological 
background [97]. Together, product- and patient-related factors influence an 
individual’s susceptibility to develop a neutralizing ADA response to BPs.  
 
1.3.2 Antibodies against recombinant interferon beta 
1.3.2.1 Immunogenicity among interferon beta products 
The immunogenicity of recombinant IFNβ was already detected during the first clinical 
trial with IFNβ-1b, in which 42% of the treated patients became NAb positive [98]. 
Development of NAbs against IFNβ was further supported by the results from trials 
with the different IFNβ-1a preparations, although the frequency of NAb positive 
patients was found to be lower for IFNβ-1a compared to IFNβ-1b [99,100]. In patients 
treated with intramuscular (i.m.) IFNβ-1a, NAbs were detected in 22% [100], whereas 
treatment with s.c. IFNβ-1a induced NAbs in 13% and 24% of the patients receiving 
the high dose (44µg) and the low dose (22µg) respectively [99]. This difference in 
immunogenicity between products has been confirmed in later studies with the NAb 
frequency ranging between 21-61% for IFNβ-1b [101,102], between 5-39% for s.c. 
IFNβ-1a at 22µg [103,104], between 13-35% for IFNβ-1a at 44µg [99,105] and 
between 1-13% for i.m. IFNβ-1a [104,106].  
 
The variation in NAb frequency among products could be influenced by several factors 
such as route of administration (i.m. or s.c.), dosage, and injection frequency. However, 
results from different trials comparing the dose and administration route for a specific 
IFNβ product have been inconclusive (reviewed in [107,108]). Overall, it seems like 
the difference in immunogenicity between the IFNβ products mostly depend on the 
type of IFNβ molecule injected. The reason for the higher immunogenicity of IFNβ-1b 
is thought to be a result of its structural differences compared to endogenous IFNβ and 
its tendency to form aggregates, since these factors would be likely to trigger B-cell 
activation. For the two IFNβ-1a preparations, the higher NAb frequency for s.c. IFNβ-
1a may be a result of its higher dosage frequency, which may increase the risk for B-
cell activation as a result of more tissue damage. In addition, the s.c. IFNβ-1a 
preparation, but not the i.m. IFNβ-1a, have been reported to contain aggregates of 
human serum albumin (HSA) [109], which may influence its immunogenicity. In this 
study it was also shown that IFNβ-1b preparations have large fractions of aggregated 
protein that is comprised of IFNβ protein but also of HSA [109]. These findings 
support the hypothesis that aggregate content is a major trigger of humoral immunity to 
BPs. However, the likelihood for a NAb-positive patient to revert to NAb-negative 
status during continued treatment is higher in patients treated with IFNβ-1b than in 
patients treated with s.c. IFNβ-1a [110,111], suggesting that tolerance is induced earlier 
with the IFNβ-1b preparation. In addition, IFNβ-1b generally induce lower NAb titers 
compared to IFNβ-a, and patients with low titers are more likely to become NAb 
negative during continued treatment [104,111].     
   
1.3.2.2 Correlation between NAb titers and IFNβ bioactivity 
Most IFNβ-treated patients (~80%) develop binding antibodies (BAbs) against IFNβ, 
and these antibodies can be already be detected after three months of treatment [112].  
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Around 50% of BAb-positive patients develop NAbs, and these antibodies usually 
develops between 6 and 18 months of treatment [106,110]. Since NAbs interfere with 
the binding of IFNβ to its receptor, NAb-positive patients have reduced expression of 
IFNβ-inducible gene products following an IFNβ injection [113-115]. One of the most 
sensitive and specific biomarkers of IFNβ bioactivity is MxA [116]. The expression of 
MxA mRNA or protein can be used to monitor development of NAbs against IFNβ 
[117-119]. In patients with high NAbs, the in vivo expression of MxA in blood is 
significantly reduced, indicating that these patients have no or very little biological 
response to IFNβ. In comparison, lower NAb titers seem to have little or no effect on 
IFNβ bioactivity since the MxA expression is comparable to that in NAb-negative 
patients [113-115].  
 
Development of NAbs is associated with reduced therapeutic efficacy, resulting in 
significantly increased relapse rates and MRI activity, as well as faster disease 
progression in NAb-positive compared to NAb-negative patients [120-123]; however, 
the clinical effects of NAbs are often not detectable until more than two years of 
treatment [120,122,124]. Instead, NAb titer levels in individual patients can be 
measured using different immunoassays [125] and cell-based assays [118,126,127]. 
This makes it possible to identify patients with NAb titers high enough to interfere with 
the bioactivity of IFNβ and who therefore are unlikely to respond to IFNβ therapy. 
Patients who lack IFNβ bioactivity because of NAb development, or who do not 
respond to treatment for some other unknown reason, should be switched to alternative 
disease-modifying drugs such as natalizumab.    
 
However, the NAb titer level at which the IFNβ bioactivity is impaired in an individual 
patient is not completely established, and furthermore this is dependent on the 
sensitivity of the assay that is being used for NAb quantification. Study II in this thesis 
was conducted with the aim to identify a biologically relevant NAb-titer cut point at 
which the in vivo bioactivity of IFNβ is blocked and if this cut point is comparable 
between two different cell-based assays used for NAb titer quantification. 
 
1.3.2.3 Patient-related factors influencing immunogenicity of IFNβ 
Although product-related factors contribute to the variation in NAb frequency between 
IFNβ preparations, these factors cannot explain why breakage of tolerance only occurs 
in a subgroup of the treated patients. BAbs against IFNβ seems to develop in the 
majority of IFNβ-treated MS patients, but only a proportion of these patients become 
NAb positive later on [112]. Thus, other factors such as the patient’s genetic and 
immunological background are likely to influence the development of a sustained 
immune response. Overall, it has been shown that NAb positive patients have higher 
IgG antibody titers than those with BAb [128]. However, there also seems to be 
qualitative differences in the antibody response between these groups, as a larger 
fraction of the anti-IFNβ IgG antibodies are of the IgG4 subclass [129]. For B cells to 
produce high-affinity antibodies of the IgG class they generally require help from 
antigen-specific CD4+ T cells [130], and this activation is dependent on HLA class II 
molecules.  
 
There is increasing evidence that immunogenicity of IFNβ is influenced by the 
patient’s HLA genotype. An association was shown between the DRB1*15:01-
DQB1*06:02 haplotype and increased proliferative response of CD4+ T-cells to 
specific IFNβ epitopes in vitro [131]. Furthermore, a study on peripheral blood 
mononuclear cells from IFNβ-treated MS patients found an association between the 
 10 
HLA-DRB1*07:01-DQA1*02:01 haplotype and IFNβ immunogenicity [132]. Recent 
studies based on larger patient materials have associated an increased risk of 
developing anti-drug antibodies against IFNβ with the HLA-DRB1*04:01 and HLA-
DRB1*04:08 alleles [133,134]. Also, genetic associations of an intergenic single 
nucleotide polymorphism (SNP) on chromosome 8q24.3 and a SNP within the HLA 
region, independent of DRB1*04:01 and DRB1*04:08, with the development of higher 
anti-drug antibody titers against IFNβ have been reported [135].  
 
In addition to genes, life style factors might influence the risk of developing NAbs 
against IFNβ. Findings suggest that cigarette smoking increases the risk of developing 
NAbs against IFNβ (IFNβ-1a), indicating that environmental and/or life-style factors 
also seem to predispose to the immunogenicity of BPs [136,137]. By identifying more 
patient- and environmental-related factors that can influence the immunogenicity of 
IFNβ, it is possible that the frequency of NAbs can be reduced in the future. In study III 
and study IV, the patients’ OCB-status and HLA genotypes, respectively, were 
investigated as possible factors influencing development of NAbs against recombinant 
IFNβ.  
 
1.3.3 Antibodies against natalizumab 
Despite its resemblance to a human IgG4 antibody, natalizumab has been shown to be 
immunogenic and capable of inducing humoral immunity in treated patients. 
Development of antibodies against natalizumab was detected in 9% and 12% of the 
patients included in the first clinical trials of natalizumab [85,86]. In both studies, the 
majority of the positive patients (88% and 96%, respectively) already had detectable 
antibodies after three months of treatment. When these positive patients were followed 
up after at least six weeks from the first positive sample, persistent antibodies were 
detected in 6% of the patients, whereas antibodies had disappeared in over one third of 
the patients (3% and 5% respectively) [138]. When the concentration of free 
natalizumab in serum was measured at different time points during treatment in these 
patients, it was observed that antibody-positive patients had a significantly lower 
natalizumab concentration than antibody negative patients, indicating that these 
antibodies increased the drug clearance from the system. By the third month, no 
difference in natalizumab concentrations was found between transiently and 
persistently positive patients. However, after seroconversion to antibody negative 
status, the serum natalizumab concentration in transiently positive patients began to 
increase, almost reaching the levels of antibody negative patients by the end of the first 
year of treatment [138]. This was further supported by the finding that persistently 
positive patients, but not transiently positive patients, had reduced therapeutic efficacy 
including higher relapse rate, MRI activity and disease progression compared to 
antibody negative patients. In addition, persistent antibody positive patients had an 
increased risk of developing infusion-related adverse events [85,86,138].  
 
Using the same enzyme-linked immunosorbent assay (ELISA) procedure as was used 
in the first clinical studies, later observational studies have found that anti-natalizumab 
antibodies develop in 4.5-14% of treated patients, of whom 1.6-9% have been 
persistently positive and 1-5% have been transiently positive [87,139,140]. Other 
studies have also found that anti-natalizumab antibodies develop early, with most 
patients becoming positive during the first six months of treatment [87,139].  
 
The transient antibody response to natalizumab observed in a subgroup of patients 
suggests that some patients become tolerant to natalizumab during continued treatment. 
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Since antibody development against natalizumab is an efficacy and safety issue in 
treated patients, it is of importance to find biomarkers to enable the identification of 
individual patients at risk of becoming persistently antibody positive. In study V of this 
thesis, the aim was to search for an antibody profile that would make it possible to 
distinguish transiently and persistently positive patients, in order to predict at an early 
stage whether a patient should discontinue treatment or not. 
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2 AIMS OF THE THESIS 
The overall aims of this thesis were to determine the prevalence and biological effects 
of ADA against IFNβ and natalizumab, and to identify factors that influence the 
immunogenicity of IFNβ in patients with MS.   
 
The specific aims of each study were the following:  
 
Study I:  
To assess how the prevalence of NAbs, the levels of NAb titers and the IFNβ 
preparations used for treatment of MS patients changed in 2009-2010 compared to 
2003-2004 when monitoring NAbs against IFNβ became clinical practice in Sweden 
 
Study II:  
To evaluate how well NAb titers against IFNβ correlate between the two bioassays 
MxA induction assay and iLite, and to determine at which titer level the in vivo 
biological activity of IFNβ is impaired in treated MS patients. 
 
Study III:  
To compare the development of NAbs against IFNβ between MS patients with and 
without OCB in the CSF in order to determine if OCB status influences the risk of 
developing NAbs against IFNβ. 
 
Study IV:  
To investigate whether HLA genes influence the risk of developing NAbs to IFNβ, and 
if so, whether the genetically determined risk of developing NAbs varies depending on 
type of IFNβ preparation. 
 
Study V:  
To characterize the ADA response against natalizumab and to investigate differences in 
the antibody response between patients who develop persistent and transient antibodies 
against the drug.  
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3 MATERIALS AND METHODS 
More detailed information is found in the “Material and Methods” sections in the 
original articles.   
 
3.1 PATIENTS AND STUDY DESIGN 
Informed consent, oral or written, was obtained from patients participating in research 
and all studies were approved by the regional ethical committee in Stockholm. Patients 
with a diagnosis of MS, according to McDonald criteria [8], analyzed for NAbs against 
IFNβ between 2003 and 2013, or screened for anti-natalizumab antibodies between 
2006 and 2011 in the routine NAb laboratory at Karolinska Institutet in Stockholm, 
were included in the works of this thesis. Laboratory test results, clinical data and 
information on treatment of relevance for the respective studies were obtained from the 
NAb registry and Swedish Multiple Sclerosis (SMS) registry (http://www.msreg.net).  
 
HLA genotype data were obtained from a genetic database containing genotype data 
from different genetic projects on MS patients in Sweden: EIMS (Epidemiological 
Investigation of Multiple Sclerosis) or GEMS (Genes and Environment in Multiple 
Sclerosis), STOP MS (Stockholm Prospective Assessment of Multiple Sclerosis), and 
IMSE I (Immunomodulatory Multiple Sclerosis study I).  
 
Study I included all (n=1296) IFNβ-treated Swedish and Icelandic MS patients who 
had at least one serum sample analyzed for NAbs during 2009 and 2010. The frequency 
of NAb-positivity and distribution of titer levels, usage of different IFNβ preparations 
and treatment duration in this cohort were compared with previously published data on 
1115 MS patients analyzed for NAbs during 2003 and 2004 [104]. In both study 
cohorts, only the result from the first analyzed sample was included for each patient.  
 
In study II, 44 IFNβ-treated MS patients, who had been previously analyzed for NAbs, 
were recruited from four neurological hospital centers in Sweden, including Karolinska 
University Hospital in Huddinge and Solna, Danderyd Hospital, and Sahlgrenska 
University Hospital, between 2010 and 2013. Patients were asked to participate on the 
basis of their previous NAb status in order to include patients with NAb titers ranging 
from negative to very high positive. After written informed consent was signed by all 
participants, peripheral blood samples were collected for isolation of RNA and serum 
to be used for mRNA and protein expression studies on IFNβ-induced biomarkers, and 
for NAb analyses.  
 
In study III, the included patients were assayed for NAbs between 2003 and 2009. 
Information regarding NAb status and IFNβ preparation use was available for 2070 
OCB-positive and 149 OCB-negative MS patients. Of these patients, date of 
treatment onset was recorded for 1886 OCB negative and 137 OCB positive, and 
HLA-DRB1genotype data was accessible for 506 OCB positive and 26 OCB negative.  
 
In study IV, data on all HLA-genotyped MS patients who had been assayed for NAbs 
against IFNβ between 2003 and 2012 were obtained. After excluding patients of non-
Scandinavian origin (n=403) to reduce population heterogeneity and patients who did 
not fulfill the criteria for NAb positivity and negativity (n=420), the study comprised 
364 NAb positive and 539 NAb negative patients. If several sources of a HLA-
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genotype were found for one patient, the data obtained from classical genotyping was 
used. Carriage of HLA-DRB1*04:01 and *04:04 was identified from imputed 
genotypes. Binding of specific HLA alleles to the two types of recombinant IFNβ 
molecules, IFNβ-1 (166 amino acids) and IFNβ-1b (165 amino acids) was predicted 
using the NetMHCII and NetMHCpan servers from the free on-line prediction 
services at CBS (http://www.cbs.dtu.dk/services/). 
 
In Study V, we had access to all Swedish natalizumab-treated MS patients who had 
been screened for anti-natalizumab antibodies between August 2006 and September 
2011. Patients who had not pre-treatment sample were excluded, resulting in a study 
cohort comprising 1391patients and a total of 5425 samples. Information on 
demographic and clinical characteristics of the patients was available for 888 patients, 
who were found to be representative for the total study cohort with regard to age, 
gender, treatment duration and total anti-natalizumab antibody responses.      
 
3.2 NEUTRALIZING ANTIBODY ASSAYS 
Detection of IFNβ-specific antibodies with capacity to neutralize the biological 
responses to IFNβ can be performed using different in vitro bioassay methods. In this 
thesis, both screening and quantitation of IFNβ therapy-induced NAbs has been 
performed using two different cell-based assays, the MxA induction assay and the 
luciferase reporter gene assay iLite. Both assays are semi-quantitative, which means 
that the neutralizing capacity of a serum is not given in absolute amount but relative 
to measurements from IFNβ standard curves. 
 
In both assays, serum samples isolated from peripheral venous blood, preferably 
collected at least 36 hours after IFNβ injection, were used. For the iLite assay, patient’s 
sera were heated for 30 minutes at 56°C to inactivate complement, whereas no 
pretreatment was required for the MxA assay [141]. Samples were stored at -20°C 
and/or -80°C before analysis.  
 
3.2.1 MxA induction assay 
The MxA induction assay for measurement of NAbs against IFNβ is a modification 
of the MxA induction assay developed for measuring bioactivity of type I IFNs in 
vitro [118,141]. In this NAb assay, neutralization of IFNβ-induced expression of 
MxA can be measured both at the protein level by ELISA [118,141] and at the 
mRNA level by quantitative real-time polymerase chain reaction (RT-PCR) [117]. 
For the work of this thesis, the MxA protein induction assay was employed for 
samples analyzed from 2003 to 2006, as described by Sominanda et al. [104], while 
samples  from 2007 and onwards were analyzed with the MxA gene expression assay 
(MGA) [117].    
 
In both assays, patient serum diluted in a fixed concentration of IFNβ (10 
international units [IU]/ml of i.m. IFNβ-1a) is added to IFNAR expressing cells (lung 
carcinoma cell line A549 from ATTC). In the presence of IFNβ-specific NAbs, the 
serum will inhibit the interaction between IFNβ and its receptor, which prevents 
induction of type I IFN-specific gene expression, e.g. MxA. The serum samples’ 
neutralizing activity, i.e. NAb titer, is defined as the serum dilution at which 10% (1 
IU/ml) of the IFNβ bioactivity remains. To determine at which serum dilution this 
ten-fold reduction occurs, a standard curve of recombinant IFNβ-1a, serially diluted 
from10 to 0 IU/ml, is added to A549. The dose-dependent induction of MxA is then 
used to calculate the quantity of MxA expressed when cells are stimulated with 1 IU/ml 
   15 
of IFNβ, also known as EC50, which is the linear region of the sigmoidal dose-response 
curve. The EC50 value generated from the standard curve is then used to assess at which 
dilution a patient serum neutralizes the IFNβ activity from 10 to 1 IU/ml. The 
reciprocal of this dilution is used to define the NAb titer, as described in section 3.2.3. 
 
3.2.2 Luciferase reporter gene assay 
In study II, NAb analyses were performed using both the MxA gene expression 
assay described above, and the iLite™ anti-human IFNβ bioassay from Biomonitor 
Limited. In the iLite assay, IFNβ bioactivity is measured using the cell-cycle arrested 
human cell line PIL5, which derives from the work done by Lallemand and 
colleagues [126,142]. These type I IFN-sensitive cells carry the firefly luciferase gene 
under the control of an IFN-responsive promoter element. In the absence of NAbs, 
IFNβ binds to its receptor and stimulates the expression of luciferase. The level of 
IFNβ-induced luciferase expression is determined through the protein’s enzymatic 
activity, which is measured as strength of the bioluminescence signal [126].  
 
As in the MxA induction assay, the neutralizing activity of patient’s serum is 
measured as its ability to reduce the activity of the added IFNβ from 10 to 1 IU/ml. 
To determine the luciferase activity that is induced by 1 IU/ml of IFNβ, the relative 
luminescence unit (RLU) is plotted against an IFNβ standard curve diluted from 80 to 
0 IU/ml. The level of luminescence measured at the midpoint of the linear part of the 
dose-response curve corresponds to 1 IU/ml of IFNβ activity, and this RLU value is 
then used to determine the dilution of patient’s serum that reduces the IFNβ activity 
from 10 to 1 IU/ml. The reciprocal of this dilution is used to define the NAb titer, as 
described in section 3.2.3.    
 
3.2.3 Calculation of neutralizing antibody titers 




Where f =reciprocal of serum dilution at 1 IU/ml, and n=the ratio of added IFNβ to 
remaining IFNβ in the sample. Using this formula, NAb titers are expressed as ten-
fold reduction units per milliliter (TRU/ml), which is recommended by the World 
Health Organization [144] and the European Federation of Neurological Societies 
task force [107]. It has been shown that NAb titers adjusted according to the Kawade 
formula and expressed as TRU/ml are comparable, although different cell-based assays 
were used to detect the neutralizing antibody titer [126,146]. 
 
3.2.4 Classification of neutralizing antibody status 
In all studies (study I, II, III and IV), patient serum samples were considered negative 
if NAbs were undetectable in the screening assay, and if NAb titers were <10 TRU/ml 
in the titration assay. Patients with a NAb titer ≥10 TRU/ml were defined as positive. In 
study I and II, NAb positive samples were categorized as shown in Table 1.  
 
Table1. NAb titer classification. 
Titer category  Study I Study II 
Low positive 10-49 TRU/ml 10-50 TRU/ml 
Medium positive 50-199 TRU/ml 51-200 TRU/ml 
High positive >200 TRU/ml >200 TRU/ml 
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In study II and IV, a titer of 150 TRU/ml was used as a cut-point for biologically 
relevant titers, as in vivo MxA expression following IFNβ administration has shown 
to be markedly reduced at this titer level [113].  
 
3.3 MEASUREMENTS OF INTERFERON-BETA BIOMARKERS 
The biological effect of NAbs can be determined by measuring the in vivo bioactivity 
of IFNβ following an injection of the drug. In the presence of NAbs there will be a 
titer-dependent reduction in the expression of IFNβ-induced genes such as MxA 
[119,128]. In study II, the in vivo IFNβ-induced expression of MxA and CXCL (C-
X-C motif chemokine)-10 mRNA in whole blood, and CXCL-10 protein in serum, 
was measured to assess the biological response to IFNβ therapy at different NAb 
titers.  
 
Total RNA was isolated from 3 ml peripheral venous blood collected 8 to18 hours 
after an IFNβ injection. RNA quality and concentration was determined before total 
RNA was reversely transcribed into cDNA. Taqman RT-PCR was performed to 
determine MxA and CXCL-10 mRNA expression. Relative gene expression of MxA 
and CXCL-10 was calculated using the 2ΔΔCt method [147], where expression levels 
were normalized to the reference gene HPRT1 (hypoxanthine-guanine 
phosphoribosyltransferase) and further calibrated against the expression of healthy 
controls.  
 
Serum was isolated from 5 ml peripheral venous blood collected both 8-18 hours and at 
least 36 hours after IFNβ injection. Concentration of CXCL-10 was measured using 
the human CXCL10/IP-10 Quantikine ELISA kit from R&D Systems, according to 
manufacturer’s protocol.  
 
3.4 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
3.4.1 Quantification of total IgG 
The concentration of IgG antibodies was measured in serum samples collected before 
first natalizumab infusion from 64 MS patients. Total IgG was quantified using the 
human IgG ELISA kit (ALP) from Mabtech. 
 
3.4.2 Natalizumab-specific antibody detection 
The total antibody response to natalizumab was determined by a bridging ELISA 
method and performed according to the standardized protocol developed by 
BiogenIdec. In brief, patient serum and control samples were added to natalizumab-
coated microtiter plates in the presence and absence of competing soluble natalizumab. 
Captured natalizumab-specific antibodies were detected using biotinylated natalizumab 
and streptavidin-horseradish peroxidase, with subsequent addition of 
tetramethylbenzidine substrate and sulfuric acid (H2SO4), before optical density (OD) 
was measured at 450 nm.  
 
Wells containing serum samples with soluble natalizumab (competition well) were 
used to confirm the binding specificity of captured antibodies detected in wells 
containing serum samples without soluble natalizumab (detection well). Samples with 
at least twice as high reactivity against natalizumab in the detection well compared to 
the competition well were considered positive, meaning that an OD ratio ≥2.0 was used 
as cut-point for antibody positivity.  
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3.4.2.1 Detection of natalizumab-specific IgM and IgG1-3 antibodies 
For detection of natalizumab-specific antibodies of the IgM class and the subclasses 
IgG1, IgG2 and IgG3, slightly modified versions of the screening ELISA described 
above were used. Natalizumab-specific antibodies of the IgG1-3 subclasses were 
detected using biotinylated monoclonal mouse anti-human IgG1-3 antibodies 
respectively. Natalizumab-specific antibodies of the IgM class were captured to 
microtiter plates coated with an anti-human IgM antibody, followed by detection 
according to the standardized protocol described above. Patient sera positive or 
negative for anti-natalizumab IgM or IgG1–3 antibodies were included as controls on 
all plates, and results were reported as OD ratios as described above. 
 
3.4.2.2 Detection of natalizumab-specific IgG4 antibodies 
Detection of natalizumab-specific antibodies of the IgG4 subclass was performed using 
an ImmunoCAP assay developed by Phadia. In this immunoassay, patient serum was 
added to ImmunoCAP tests coupled with F(ab’)2 fragments of natalizumab. Captured 
natalizumab-specific IgG4 antibodies were detected using the instrument Phadia 100. A 
concentration of 0.125 mg Antigen/liter was used as cut-point for positivity, which was 
based on the mean value + 2 standard deviations of 18 healthy control donors.  
 
3.5 GENOTYPING 
Classical genotyping for the HLA-A, HLA-C and HLA-DRB1 genes was performed 
using kits from Olerup SSP AB [148] and for the HLA-B gene, a Luminex-based 
reverse SSO method was used. HLA-genotypes were also obtained through imputation, 
either with genotypes from the IMSGC WTCCC2 MS genome wide association study 
[33] or from the Immunochip [149], using HLA*IMP:01 [150] and HLA*IMP:02 [151] 
respectively.  
 
3.6 CEREBROSPINAL FLUID (CSF) ANALYSIS 
CSF analyses were performed during the diagnostic workup for each patient. 
Oligoclonal IgG bands (OCB) were detected in paired CSF and plasma samples using 
isoelectric focusing followed by IgG-specific immunolabelling [152]. Increased 
intrathecal IgG levels were measured using the IgG index 
(IgGCSF/IgGplasma)/(albuminCSF/albuminplasma), which correct for possible dysfunction of 
the blood-CSF barrier [153]. In study III, OCB positivity was defined as having two 
or more OCB in CSF that differ from plasma and/or increased intrathecal synthesis of 
IgG, according to the McDonald criteria [8].  
 
3.7 STATISTICS 
All reported probability, p, values were based on two-sided statistical tests and 
considered significant if below an alpha-level of 0.05. Analyses were performed using 
GraphPad Prism from GraphPad Software Inc., USA, or the free software package R 
[154]. 
 
Patient characteristics were presented as mean or median, with ± SEM (standard error 
of mean), IQR (interquartile range) or min-max range, for continuous variables and as 
absolute numbers and frequencies for categorical variables. 
  
The Shapiro-Wilk test was used to verify normal distribution of the data. The two-
sample t-test was used when analyzing unpaired data with normal distribution. When 
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normality was not assumed, the non-parametric Mann-Whitney test was used for 
unpaired data, whereas the Wilcoxon-matched-pairs signed rank test was used for 
comparisons between paired data. Furthermore, the non-parametric Spearman 
correlation test was used to determine relationships between two variables. 
 
For analyses of categorical data, the Fisher’s exact test or chi-square test, with or 
without Yates’ correction, were used for comparisons between two groups, while the 
Kruskal-Wallis test with Dunn’s multiple comparison was used for comparisons 
between three groups. In study I, a Cochran-Mantel-Haenszel test was used to 
determine the overall significance of NAb development between the study cohorts 
when controlling for the covariates, i.e. the different IFNβ preparations. 
 
Correction for multiple testing was done with the Bonferroni method to compensate for 
the number of comparisons made. This was done in studies I and IV to control the 
probability of false positive findings. 
 
Logistic regression analyses were performed to control for confounding effects and 
interaction between the variables OCB status and IFNβ preparation on NAb outcome in 
study III. 
 
Odds ratio (OR) calculations were performed to measure the strength of association 
between OCB status and NAb positivity (study III), and between HLA allele group 
carriage and NAb positivity and development of biologically relevant titers (study IV). 
 
Absolute risk (AR) was calculated in study IV for development of NAbs and 
biologically relevant titers to measure the influence of HLA allele group carriage within 
each of the three treatment groups. The AR was estimated using Bayes’ theorem [155].    
In this formula, the AR of reaching the outcome (NAb positivity/high titers) is based on 
the proportion of patients in the Swedish NAb registry that achieved these outcomes 
within each treatment group (i.e. the proportion of patients that developed NAbs and 
high NAb titers for each preparation). 
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4 RESULTS AND DISCUSSION 
4.1 STUDY I 
Routine analysis for NAbs against IFNβ became available in Sweden in 2003 and soon 
after that the monitoring of NAbs became clinical practice. In a previous study that 
included 1115 Swedish and Icelandic MS patients treated with IFNβ, who were 
routinely analyzed in 2003-2004 for the presence of NAbs, 32% of the patients were 
identified as NAb positive and high antibody titers above 200 TRU/ml were present in 
as many as 16% of the whole study group [104].  
 
In this study we investigated whether the prevalence and titer levels of NAbs as well as 
the distribution of IFNβ preparations used had changed from when the routine 
monitoring started in 2003-2004 compared to 2009-2010.  
 
4.1.1 Decreased seroprevalence over time 
When comparing the data from the 1296 IFNβ-treated MS patients from Sweden and 
Iceland that were routinely analyzed for NAbs between 2009 and 2010 with the 
previously published data that included 1115 patients, the overall seroprevalence of 
NAbs had decreased markedly from 32% to 19% between 2003-2004 and 2009-2010 
(Table 2). Interestingly, a decrease in NAb positivity was only seen in patients treated 
with the IFNβ-1a preparations whereas the percentage of NAb positive patients among 
those receiving IFNβ-1b remained constant (Table 2). 
 
Table 2. Seroprevalence of NAbs in 2003-2004 compared to 2009-2010. 
 2003-2004 2009-2010 
 Total Distrib. 
(%) 





n (%) P-value* 
All patients 1115 n/a 356 (32) 1296 n/a 250 (19) 9.9x10-13† 
i.m. IFNβ-1a 257 23 34 (13) 586 45 32 (5) 0.00044 
s.c.IFNβ-1a (22) 276 25 108 (39) 46 4 13 (28) NS 
s.c.IFNβ-1a (44) 294 26 89 (30) 316 24 53 (17) 0.00032 
IFNβ-1b 288 26 125 (43) 348 27 152 (44) NS 
* Corrected P-values are reported for NAb frequency comparisons of drug preparations between 2003-
2004 and 2009-2010.  
† A Cochran-Mantel-Haenszel chi-squared test yielded a p-value of 1.5x10-5 across the treatments. 
n/a=not applicable, NS=not significant 
 
4.1.2 Changes in NAb titer levels over time 
Moreover, there was a change in NAb titer levels between 2003-2004 and 2009-2010 
and the greatest, and most important, change occurred in the group of patients with high 
NAb titers, where a decrease from 16% to 7% was seen. After stratification based on 
titer levels and IFNβ preparations, a significant decrease was only noted in the high titer 
group of patients receiving IFNβ-1a (Avonex and Rebif 44).  
 
When comparing the proportion of seropositive patients over time the overall 
seroprevalence had decreased for all time points investigated (Figure 1). A difference in 
seropositivity could mainly be seen for patients that had been on treatment for 4-5 
years, as the seroprevalence decreased from 41% to 13% between 2003-2004 and 
2009-2010 (Figure 1). Interestingly, when looking at the different NAb titer categories, 
the proportion of patients with low positive titers was higher for all time points in 2009-
2010 while the proportion with high titers was lower compared to 2003-2004. The 
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higher proportion of low titer positive patients might indicate that patients with low 
positive titers are recommended to stay on IFNβ treatment since these NAb levels are 
unlikely to suppress the therapeutic efficacy.  
 






Together these results suggest that the incorporation of routine NAb testing into clinical 
practice, and the fact that clinicians seem to take these results into consideration when 
making treatment decisions, has had an effect on NAb seroprevalence and titer levels in 
Sweden and Iceland during the five years between the studies. In addition, the reason(s) 
for the lower proportion of NAb positive patients, especially those with high antibody 
levels, may also be the preferential use of less immunogenic products or improvements 
of drug formulations that result in lower immunogenicity against IFNβ. There is 
general agreement that i.m. IFNβ-1a is the least immunogenic preparation, and in this 
study we observed that the proportion of patients treated with this product had 
increased significantly between the periods, from 23% in 2003-2004 to 45% in 2009-
2010. We could also see that the use of the lower dose (22µg) of s.c. IFNβ-1a, which 
has been suggested to be more immunogenic than the high dose preparation, had 
decreased substantially and this might be reflected in the overall reduction in NAb 
frequency.  
 
Furthermore, the decreased frequency of NAb positive patients might be a result of the 
efforts by the pharmaceutical companies to produce IFNβ preparations with lower 
immunogenicity. The lower proportion of NAb-positive patients in the group of 
patients treated with s.c. IFNβ-1a might be explained by the introduction of a less 
immunogenic formula, the Rebif New Formulation (RNF), in Sweden in October 2007 
[156]. It is also possible that patients treated with i.m. IFNβ-1a in 2003-2004 had 
received prior treatment with the earlier and more immunogenic formulation [157], 
which might account for the observed reduction of NAbs in patients receiving i.m. 
IFNβ-1a.  
 
Finally, the use of different methods to detect and quantify NAbs had changed between 
the periods. It is possible that the MxA gene expression assay used in the later study is 
less sensitive than the MxA protein assay. However, the constant proportion of NAb-
positive patients in the IFNβ-1b treated group speaks against this explanation.  
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4.2 STUDY II 
The objective of this study was to quantify and compare IFNβ NAb titers analyzed with 
the MxA induction assay, MGA, and the luciferase induction assay, iLite, and to 
correlate respective NAb titer readouts with expression levels of the IFNβ-induced 
genes MxA and CXCL-10.  
 
Of the 44 IFNβ-treated MS patients analyzed in this study, 8 received i.m. IFNβ-1a, 11 
received s.c. IFNβ-a and 25 received s.c. IFNβ-1b. Serum samples for NAb analysis 
were available for all 44 patients, and these samples were collected 11-162 hours (mean 
70 hours) after the latest IFNβ injection. NAb positivity was defined as a titer ≥10 
TRU/ml in both assays. In MGA, 28 patients (64%) were classified as positive with 
titers between 10 and 6467 TRU/ml, compared to 21 patients (48%) in iLite with titers 
between 11 and 11584 TRU/ml. Although 7 patients with low titers in MGA were 
negative in iLite, and 8 patients with medium titers in MGA were either low positive 
(n=2) or high positive (n=1) in iLite (Table 3), we found that NAb titers strongly 
correlated between assays (Spearman r=0.94, 95% CI 0.88-0.97). 
 
Table 3. Comparison of NAb titers against IFNβ measured by MGA and iLite.  
MGA, TRU/ml 
iLite, TRU/ml 
<10 (n=23) 10-50 (n=5) 51-200 (n=5)  >200 (n=11) 
<10 (n=16) 16 0 0 0 
10-50 (n=10)  7 3 0 0 
51-200 (n=8)  0 2 5 1 
>200 (n=10) 0 0 0 10 
MGA = myxovirus resistance protein A gene expression assay; TRU/ml = ten-fold reduction units per 
milliliter 
 
4.2.1 Biologically functional NAb titer cut-point 
Bioactivity of IFNβ at different NAb titers was assessed by measuring the in vivo 
IFNβ-induced MxA and CXCL-10 gene expression 8-18 hours (mean 11.6 hours) post-
IFNβ injection in 42 patients. There was significant negative correlations between MxA 
and CXCL-10 mRNA expression and patients’ NAb titers measured with both MGA 
(MxA: Spearman r= -0.88, 95% CI -0.94 to -0.79; CXCL-10: Spearman r= -0.91, 95% 
CI -0.95 to -0.83) and iLite (MxA: Spearman r= -0.89, 95% CI -0.94 to -0.81; CXCL-
10: Spearman r= -0.90, 95% CI -0.94 to -0.81).  
 
To evaluate whether the serum level of CXCL-10 also is a sensitive biomarker for 
IFNβ response, CXCL-10 concentrations were measured in 32 serum samples collected 
8-14 hours (T1) and ≥ 36 hours (T2) post-IFNβ injection. At both time points, there 
was a significant negative correlation between CXCL-10 levels and NAb titers 
measured with MGA (T1: Spearman r= -0.83, 95% CI -0.92 to -0.66; T2: -0.57, 95% 
CI -0.78 to -0.25) and iLite (T1: Spearman r= -0.88, 95% CI -0.94 to -0.77; T2: -0.74, 
95% CI -0.87 to -0.52). However, CXCL-10 levels were significantly reduced between 
T1 and T2 in (mean 468 pg/ml vs. 235 pg/ml, p < 0.0001), indicating that serum 
CXCL-10 is a sensitive biomarker for responsiveness to IFNβ if measured around 8-14 
hours after IFNβ injection.  
 
Our group has previously shown that the in vivo bioactivity of IFNβ is reduced by 80% 
in patients with NAb titers >150 TRU/ml compared to NAb negative patients, when 
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NAb titers were measured with the MxA protein induction assay [113]. When using the 
same biological cut-point for NAb titers determined by the MGA and iLite assay, we 
found that both MxA and CXCL-10 mRNA expression was reduced by 97% in NAb 
positive compared to negative patients (Figure 2). Thus, a medium NAb titer of 
150/TRU/ml indicates complete neutralization of the in vivo response to IFNβ therapy, 
and can be used as a biologically functional cut-point for both assays. 
 
Figure 2. Relative mRNA expression (RQ) of MxA and CXCL-10 in patients with different 





The MxA gene expression induction assay (MGA) has been used for screening and 
quantification of NAbs against IFNβ in the NAb laboratory at Karolinska Institutet 
since 2006-2007. This bioassay requires high maintenance and is time consuming to 
perform; therefore we were looking for a more easy-to-perform bioassay, capable of 
both detecting and quantifying NAbs with similar sensitivity and accuracy to MGA. 
 
From these results, we conclude that the iLite bioassay can replace our in-house MxA 
induction assay for routine monitoring of NAbs against IFNβ. Furthermore, a medium 
NAb titer of 150 TRU/ml seems to be a good cut-point to define a significant reduction 
or total absence of IFNβ bioactivity in treated MS patients, since the IFNβ-induced 
expression of both MxA and CXCL-10 was completely neutralized over this cut-point.  
 
We observed that the MGA assay has somewhat higher sensitivity to detect low NAb 
titers compared to iLite, as shown by the difference in classification of seven serum 
samples. However, this is not considered to be a significant problem, since NAb titers 
in the lower ranges seem to have minor effect on the in vivo biological response to 
IFNβ. 
 
Although there have been some controversies regarding the clinical relevance of NAbs, 
it seems unlikely that therapeutic efficacy would be maintained even though the in vivo 
expression of type I IFN biomarkers, e.g. MxA and CXCL-10, is almost completely 
inhibited in patients with high NAb titers. Interestingly, the CXCL-10 expression was 
unexpectedly low in a subgroup of the NAb-negative patients, regardless of which 
assay that was used to establish the NAb status (Figure 2). Non-antibody mediated 
neutralization of IFNβ bioactivity has been observed in a small percentage (~4%) of 
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IFNβ-treated MS patients [158]. These patients may represent a subgroup of patients 
who are non-responders to IFNβ even in the absence of NAbs. Thus, these patients 
possibly need to shift to non-IFNβ therapy.  
 
It is important to remember that differences in the detection and quantification of NAbs 
against IFNβ depend not only on type of assay used in clinical monitoring, but also on 
variations in assay performance between different laboratories [159]. Thus, a cut-point 
of 150 TRU/ml may not be the correct cut-point for other types of NAb assay methods, 
and not even for the iLite assay if used in other laboratories where NAb monitoring is 
performed. For results to be comparable between different laboratories and clinical 
studies, it would be necessary to agree upon an assay to be used for NAb monitoring 
and to validate this method according to standard protocols. 
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4.3 STUDY III 
OCB-positive and OCB-negative MS patients have been shown to constitute two 
immunogenetically distinct subgroups of MS since they are associated with different 
HLA-DRB1 alleles, HLA-DRB1*15 and HLA-DRB1*04, respectively [23,24]. The 
reason for the absence of these MS characteristic IgG antibodies in a minor 
proportion of MS patients is unidentified. In this study we were interested in 
investigating the hypothesis that a potential alteration in the humoral immune response 
between these two patient subgroups would result in different propensities of 
developing NAbs against IFNβ. 
 
4.3.1 Association between NAb outcome and OCB status 
Of the 2219 MS included patients for whom we had information on OCB status, NAb 
status and treatment use, OCB positivity was 93% (n=2070), which is within the range 
of what has previously been reported (reviewed in [9]). When comparing the proportion 
of NAb positive patients between the groups, OCB-negative patients were found to 
develop NAbs against IFNβ to a significantly lesser extent compared to OCB-positive 
patients (19% versus 28%, p=0.02). Since treatment duration is a known risk factor for 
NAb development the time from treatment onset to collection of NAb samples was 
compared between OCB-negative and OCB-positive patients as well as between NAb-
negative and NAb-positive patients. However, treatment duration did not differ 
between the groups and was thus considered to have no impact on the observed 
difference in NAb seroprevalence between patients with and without OCB.  
 
4.3.2 Differences in immunogenicity of interferon beta-1a 
Another factor known to affect NAb development is the type of IFNβ preparations 
used, with IFNβ-1b generally being more immunogenic than IFNβ-1a (reviewed in 
[160]). Therefore, we also sought to determine whether the immune response to the 
different IFNβ preparations, IFNβ-1a and IFNβ-1b, differed between the OCB-
positive and OCB-negative group. Interestingly, when stratifying the study group for 
both OCB status and IFNβ preparation, we found that OCB-negative patients 
receiving treatment with IFNβ-1a were significantly less likely to become NAb 
positive compared to OCB-positive patients receiving IFNβ-1a (p=0.005), whereas no 
difference in NAb positivity was seen for those receiving IFNβ-1b (p=0.86) (Figure 
3).   
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4.3.3 Possible influence of HLA allele carriage 
These unexpected results led us to the hypothesis that the antigen presenting ability 
might differ between the groups, resulting in lower immune activation and antibody 
production against IFNβ-1a in OCB-negative patients. This hypothesis was also 
supported by the fact that the HLA class II alleles HLA-DRB1*04:01 and *04:08 
recently had been associated with increased risk of developing NAbs to IFNβ [134]. 
Unfortunately, data on HLA-DRB1 allele carriage was only accessible for 532 included 
patients, which was too few to investigate whether our finding could be affected by 
differences in DRB1 carriage. However, we could confirm the previously reported 
associations to distinct HLA-DRB1 alleles for the two MS subgroups, HLA-DRB1*15 
for OCB-positive MS and HLA-DRB1*04 for OCB-negative MS. The accuracy of 
these results is strengthened by a recent publication confirming the association of OCB 
status to these distinct HLA alleles [22].    
 
4.3.4 Confounding factor 
A possible confounding factor in our study is that CSF analyses performed at different 
laboratories could differ in sensitivity to detect OCB. However, the proportion of OCB- 
negative patients does not differ from that seen in previous studies; thus it seems less 
likely to be the cause of a biased selection. Even though some samples might have been 
falsely detected as OCB negative, this would at worst reduce the association seen to the 
OCB-negative group, and should not undermine our positive findings.   
 
4.3.5 Discussion 
In conclusion, the results from this OCB phenotype-NAb status analysis show that 
therapeutic IFNβ, more specifically the IFNβ-1a preparations are less immunogenic 
to, or maybe more immunologically tolerated by OCB-negative compared to OCB-
positive MS patients. Thus, we have identified an additional patient-related factor that 
affects the development of NAbs in IFNβ-treated MS patients. 
 
Absence of OCB and the less frequent immunological response towards therapeutic 
IFNβ might imply that more extensive immunological differences between OCB-
negative and OCB-positive patients exist. Whether there are other alterations in the 
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humoral immune response between these two groups of MS patients would be very 
interesting to investigate. For example, this could be investigated by looking at 
differences between the groups in their IgG responses following vaccinations and 
against common herpes viruses such as cytomegalovirus (CMV), EBV, HHV-6 and 
varicella zoster virus (VZV). A recent finding that these two subgroups of MS differ 
genetically, not only in HLA genes [22], could indicate that clinical differences seen 
in previous studies depend on the different genetic backgrounds in these patients. 
Absence of OCB might reflect that these patients constitute a subpopulation of MS 
with a specific immunological phenotype that results in less aggressive 
immunological responses, both in terms of MS pathogenesis and in a broader sense.  
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4.4 PAPER IV 
Recent investigations have connected the immunogenicity of IFNβ to specific HLA-
DRB1 alleles [133-135]. In this study, we investigated if HLA class I and class II genes 
are associated with the susceptibility to develop NAbs as well as NAb titers high 
enough to be biologically relevant. We used a Swedish cohort of 364 NAb positive and 
539 NAb negative MS patients treated with IFNβ.  
 
4.4.1 HLA allele groups associated with NAb development 
Overall, we found that HLA-DRB1*15 carriage both increased the risk of developing 
NAb (OR 1.43, 95% CI 1.17-1.74) and biologically relevant titers (OR 1.58, 95% CI 
1.25-2.0). For HLA-B*07 carriers the risk of developing biologically relevant titers was 
increased six-fold compared to non-carriers. Contrary to previous studies [133-135], the 
overall carriage frequency of the HLA-DRB1*04 allele group did not differ between 
NAb positive and NAb negative patients (NAb development: OR 1.08, 95% CI 0.83-
1.39; biologically relevant titers: OR 1.21, 95% CI 0.9-1.63). 
 
4.4.2 Interferon beta preparation-dependent HLA associations 
Since the immunogenicity of IFNβ is recognized to vary among preparations, we 
continued to investigate how NAb development is influenced by HLA carriage in 
combination with the different types of IFNβ preparations. Based on the preparation 
used at the time of NAb analysis, patients were stratified into the treatment groups 
intramuscular IFNβ-1a (n=346), subcutaneous IFNβ-1a (n=355) and IFNβ-1b (n=196). 
Using this approach, associations to distinct HLA allele groups was observed for the 
different treatment groups, HLA-DRB1*04 for IFNβ-1b and HLA-DRB1*15 for both 
types of IFNβ-1a preparations. Interestingly, we observed a trend towards reduced risk 
of developing biologically relevant NAb titers in HLA-DRB1*15 carriers receiving 
IFNβ-1b (OR 0.33, nominal p value=0.0052, BF corrected p value=0.098).  
 
Since an association to the previously reported risk allele HLA-DRB1*04 was only 
observed in patients receiving IFNβ-1b in our cohort, we performed subgroup analysis 
of HLA-DRB1*04 alleles in these patients. This analysis revealed that HLA-
DRB1*04:01 carriers have an increased risk of developing NAbs (OR 3.43, 95% CI 
1.48-7.93). However, an association to the HLA-DRB1*04:04 allele, which has been 
nominally associated to reduced risk of developing anti-IFNβ antibodies [133,134], 
could not be replicated in our cohort.  
 
The different genetic predispositions to NAb development depending on type of IFNβ 
preparation made us examine whether these HLA alleles were more or less likely to 
bind to any specific IFNβ-1a or IFNβ-1b peptides that could explain the distinct 
associations. The only observed difference in the binding analysis was that HLA-
DRB1*04:01 was more likely to bind certain IFNβ-1b peptides compared to the non-
associated alleles HLA-DRB1*04:04 and HLA-DRB1*15.  
 
Calculation of absolute risk was used to estimate how carriage of HLA-DRB1*04 and 
HLA-DRB1*15 impact the risk of developing NAbs and biologically relevant titers 
beyond the risk given by the treatment itself. This showed that carriage of HLA-
DRB1*15 increases the risk substantially for both outcomes in s.c. IFNβ-1a treated 
patients, and to a lesser extent in those receiving i.m. IFNβ-1a, whereas carriage of 
HLA-DRB1*15 lower the risk in patients receiving IFNβ-1b. In HLA-DRB1*04 
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carriers, the reversed relationship was observed (Table 4). Furthermore, the absolute 
risk for NAb development and biologically relevant titers was constantly lower for i.m. 
IFNβ-1a compared to the s.c. IFNβ-1a and -1b preparations , irrespective of whether 
the risk alleles HLA-DRB1*04 and HLA-DRB1*15 were present or absent.  
 
Although HLA-DRB1*15 predisposes to development of NAbs against the two IFNβ-
1a preparations, which contain identical IFNβ molecules, our results also indicate that 
product-related factors greatly affect immunogenicity. This is demonstrated by the 
difference in NAb prevalence, which is considerably lower in patients receiving i.m. 
compared to s.c. IFNβ-1a. For example, more frequent injections of higher doses into 
the skin, which harbors high numbers of professional antigen-presenting cells that will 
encounter the antigen [161], are more likely to trigger an immune response compared 
to less frequent low-dose injections in the muscles. The combination of these factors 
makes i.m. IFNβ-1a the least immunogenic preparation, regardless of genotype 
carriage. 
 
Table 4. Absolute risk analysis with IFNβ preparation and presence or absence of HLA-
DRB1*04 and HLA-DRB1*15 as factors influencing the susceptibility of developing NAb and 
biologically relevant titers of NAb. 
 










i.m. IFNβ-1a 6.7  9.9  11.3  5.8  9.0  
s.c. IFNβ-1a 25.0  37.8  43.3  15.6  33.6 
s.c. IFNβ-1b 63.5  40.6  42.3  60.1 49.3 
 










i.m. IFNβ-1a 3.6  4.0  5.8  1.4  3.9 
s.c. IFNβ-1a 14.9 21.2  27.7 4.5  19.0 
s.c. IFNβ-1b 28.2 10.0  10.4 26.0 15.9 
* Baseline risk is the NAb registry based frequency of all IFNβ-treated MS patients who developed NAb 
and biologically relevant titers, i.e. a NAb titer >150 TRU/ml, for each treatment.   
 
4.4.3 Discussion 
HLA genotype influences the susceptibility to develop NAbs in the Swedish 
population, confirming that genetic factors predispose to the immunogenicity of IFNβ 
therapy [133-135], although the observed effects were modest compared to the 
influence of the respective IFNβ products themselves.  
 
The identified associations to different HLA class II alleles are not unexpected given 
the central role of HLA class II molecules in peptide presentation to and activation of 
antigen-specific CD4+ T cells, which in turn provides necessary signals for persistent 
B-cell activation and induction of strong antibody responses [130]. Conversely, the 
overall association to HLA-B*07 is more difficult to interpret since there is no clear 
connection between HLA class I molecules and induction of humoral immunity. 
However, it is very likely that HLA-DRB1*15 and HLA-B*07 represents the same 
signal since HLA-B*07 is frequently present on the HLA-DRB1*15 haplotype because 
of high linkage disequilibrium between these allele groups. This is supported by 
   29 
disappearance of the HLA-B*07 association in the stratification for HLA-DRB1*15 
carriage in s.c. IFNβ-1a treated patients. We can, however, not decipher which of the 
alleles in the HLA-B*07, DRB1*15:01, DQA1*01:02, DQB1*06:02 haplotype that is 
responsible for this association. 
 
Our results indicate that there seems to be different genetic factors determining the 
immunogenicity of the two different forms of human recombinant IFNβ molecules; 
HLA-DRB1*15 for IFNβ-1a produced in mammalian cells, and HLA-DRB1*04 for 
IFNβ-1b produced in Escherichia coli. Results from the predicted binding analysis 
imply that the peptide-binding motif of HLA-DRB1*04:01 has better binding-affinity 
for IFNβ-1b peptides containing the cysteine-to-serine substitution at position 17. The 
results may also indicate that HLA-DRB1*04:01 has high binding-affinity for IFNβ-1b 
peptides containing non-glycosylated asparagine at position 80. These product-specific 
HLA associations should be further investigated, preferentially by identifying peptides 
that bind to the HLA molecules in vivo in IFNβ-1a and IFNβ-1b treated individuals. 
 
In this study, immunogenicity of IFNβ were detected using an in vitro neutralizing 
antibody assay and only patients who were positive for neutralizing anti-IFNβ 
antibodies were included, whereas in previous studies both binding and neutralizing 
anti-IFNβ antibodies were measured [133,134]. In addition to the different methods and 
definitions of antibody positivity, differences in HLA allele frequencies and distribution 
of treatments in the studied cohorts could lead to disparities in results between our 
study and previous studies by a German group [133,134]. 
 
This is the first study to describe associations to distinct HLA alleles for the two types 
of IFNβ molecules and it is possible that our finding occurred by chance, thus this 
finding needs to be confirmed in other studies with larger number of patients.  
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4.5 PAPER V 
At the time of this study, in September 2011, almost 1600 natalizumab-treated MS 
patients had been routinely assayed for the presence of anti-drug antibodies against 
natalizumab in the NAb laboratory at Karolinska Institutet, as part of a post-marketing 
surveillance study of natalizumab treatment in Sweden. Since this is one of the largest 
single-center cohorts of natalizumab-treated MS patients being analyzed for 
development of anti-natalizumab antibodies, one objective of this study was to assess 
the prevalence of anti-natalizumab antibodies in a nation-wide clinical-based setting.  
   
4.5.1 Prevalence of anti-natalizumab antibodies 
Screening results from the 1391 included patients revealed that 0.9% of the patients 
(n=12) had a pre-treatment sample that was classified as antibody positive, although the 
reactivity against natalizumab was low compared to other positive samples and 
disappeared in nine out of twelve patients after treatment onset. This unexpected pre-
treatment reactivity could be inflicted by the occurrence of rheumatoid factors (RFs) in 
these sera. RFs are low-affinity IgM antibodies directed against the Fc fragment of IgG 
and these autoantibodies, which are most often detected in individuals with suspected 
rheumatoid arthritis, are known to cause false positive results in immunogenicity assays 
[162]. Although all patients were negative for RFs the sera might contain other anti-
immunoglobulin antibodies [163-165] leading to unspecific binding to natalizumab. 
Another potential reason for the pre-treatment reactivity, which cannot be excluded, is 
that these patients had received previous treatment with natalizumab without this being 
recorded on the referral forms or in the SMS registry.  
 
After exclusion of patients with uncertain reactivity to natalizumab a total of 57 patients 
were considered positive for anti-natalizumab antibodies, giving an overall 
seroprevalence of 4.1% (57 out of 1379 patients). As previously observed, we found 
that antibody responses to natalizumab develop early after treatment onset [139,166]. In 
96% of the positive patients, anti-natalizumab antibodies were detected in the first 
collected sample, after median treatment duration of three months (range 1-12 months). 
Except for the significantly shorter treatment duration at first sampling in the antibody 
positive group compared to the antibody negative group (3 months vs. 5 months) no 
other patient characteristic factors were observed to differ between the groups. 
 
Further, sub-classification of positive patients revealed that 19 patients were 
persistently positive and 20 patients were transiently positive for anti-natalizumab 
antibodies. Since one third of the patients lacked a confirmatory follow-up sample, they 
were considered unconfirmed positive, and these 18 patients were not included in the 
subsequent analyses described below.   
 
4.5.2 Prediction of persistent antibody response    
The antibody response to natalizumab was further examined, with the aim to search for 
differences between transiently and persistently positive patients that could make it 
possible to predict if a patient is likely to become persistently positive or not.  
 
Although the isotype and subtype specific analyses of the first positive sample from all 
transiently and persistently positive patients indicated that levels of anti-natalizumab 
IgM, IgG and IgG4 antibodies were significantly different between the groups, none of 
these antibody isotypes were specific or sensitive enough to be predictors for antibody 
status outcome. Instead we found that results from the standardized ELISA used in 
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routine screening could be used for distinguishing the groups from each other, since 
persistently positive patients had significantly higher total anti-natalizumab antibody 
levels compared to transiently positive patients. By calculating the ratio between the 
OD values from detection and competition wells, thus correcting for any non-specific 
reactivity of each sample, we identified an OD ratio of 40 to be a good cut-point for 
discriminating between the groups. Thus, by applying this calculation and using the 
established cut-off point we could predict the outcome, i.e. transient or persistent 
antibody status, in 80% of the cases only by using the first positive test results obtained 
from the screening ELISA.  
 
In addition, when using an OD ratio of 40 as a cut-off point for the screening results 
from patients with unconfirmed positivity, 12 of the 18 patients had an OD ratio above 
40 and were predicted to become persistently antibody positive. If correctly predicted, 
one might expect the overall frequency of persistently positive patients to be slightly 
higher than 1.4% and closer to 2% (Figure 5).   
 
Figure 5. Total antibody response of the anti-natalizumab antibodies. The first positive 
samples after treatment start from transiently (n=20), persistently (n=19) and unconfirmed 
(n=18) antibody-positive patients. Samples with an antibody concentration ≥ 3μg/ml are shown 
as crossed shapes. Samples with an antibody concentration of 0.5-3μg/ml are shown as filled 
shapes. The grey line indicates the predictive value for antibody persistence. The dotted line 




4.5.3 Possible limitations of the study  
We found that the overall occurrence of anti-natalizumab antibodies was 4.1%, which 
is slightly lower but still in accordance with what others have shown. Anti-drug 
antibodies have previously been detected in 4.5-14.1% of natalizumab-treated MS 
patients, of whom 1-4.7% had transiently occurring antibodies and 3.5-9.4% had 
persistently occurring antibodies [87,138-140,167]. Common for these studies, 
including our study is that the same standardized bridging ELISA method, developed 
by BiogenIdec, was used for screening of samples. Based on these results, the risk of 
developing ADA against natalizumab appeared to be a minor problem compared to 
other biopharmaceuticals.  
 
However, the immunogenicity of natalizumab might be significantly higher than 
previously thought. In a paper published only weeks after our work was accepted, the 
authors could show that by using a radioimmunoassay (RIA) for antibody detection, 
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58% of patients were positive for anti-natalizumab antibodies at least once during the 
study [168]. This variation between studies is most likely the result of different 
methodologies used for assaying immunogenicity, as RIA methods are known to be 
more sensitive compared to ELISAs. The RIA method has also been shown to perform 
better at detecting anti-drug antibodies when free drug is present in the serum, since the 
bridging ELISA is more sensitive to drug interference [169]. Even so, both assays lack 
the ability to detect antibodies that have formed immune complexes with soluble 
natalizumab. Thus, it is likely that the proportion of antibody positive patients is largely 
underestimated in all of the studies performed so far.  
 
One way of circumventing the problems with assay variability and immune complex 
formation is to measure serum natalizumab concentrations in order to predict treatment 
response in individual patients, since low serum natalizumab concentrations, below 1.0 
µg/ml, seems to predict lack of treatment efficacy [168].  
 
Although the ELISA may lack sensitivity to detect low levels of antibodies, with the 
possible consequence that we have underestimated the proportion of antibody-
positive patients in our study, our results are still of clinical relevance. Since the cut-
off point for positivity in the assay has been shown to correlate with the biological 
effect on serum levels of natalizumab [138], we are likely to detect those patients who 
develop antibody levels high enough to have a significant negative impact on the 
treatment effect. 
 
4.5.4 Clinical relevance of findings 
This study shows that by performing a single analysis using a screening ELISA, we can 
not only identify patients who are positive for anti-natalizumab antibodies but also 
determine whether antibody levels in positive samples are high enough to indicate a 
persistent immune response against natalizumab.  
     
The diagnostic accuracy to predict persistence was slightly lower with our approach 
compared to the titration ELISA method described by Jensen et al. [167] (80% versus 
90%). However, since our method requires no additional analyses of positive samples it 
is less time consuming and less costly, which is advantageous for routine analysis. 
Furthermore, our results are based on a standardized protocol that is proven to give 
reproducible results.  
 
Previous recommendations for the re-monitoring of positive patients have been that 
everyone should be re-tested after at least six weeks. With support from the results of 
this study, we advise that positive patients with high antibody levels (OD ratio> 40) 
should be re-tested after four to eight weeks to confirm high antibody levels. In positive 
patients with lower titers (OD ratio <40), re-testing is advised after an extended time of 
three to six months. Meanwhile, treatment should be continued, unless hypersensitivity, 
other adverse events or treatment failure is suspected that require treatment 
discontinuation. 
 
Based on these results, we can improve the monitoring of patients developing 
antibodies against natalizumab, which will assist clinicians when making decisions on 
whether a patient should discontinue treatment or not. 
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5 CONCLUDING REMARKS 
Development of new recombinant human protein therapeutics for the treatment of a 
wide range of disorders such as MS and other chronic inflammatory diseases is 
increasing, making it even more important to prevent the development of ADAs.  
Identification of product-related factors that contribute to drug immunogenicity such as 
protein modifications, aggregate formation, and drug delivery regimes will hopefully 
result in less immunogenic treatments in the coming years.  
 
Although the variation in NAb frequency between IFNβ preparations likely depends on 
differences in for example, frequency and site of injection, molecular and structural 
modifications and product purity, these differences do not entirely explain why most 
patients are immune tolerant to IFNβ. The results from study III and IV, imply that 
there may be shared immunological and genetic risk factors for the two IFNβ-1a 
preparations containing identical molecules, whereas the shared drug delivery site most 
likely contribute to the significantly higher immunogenicity of the two subcutaneously 
injected preparations IFNβ-1a and IFNβ-1b.  
 
So far, only HLA has been shown to determine the immunogenicity of IFNβ, however, 
other genetic factors than HLA might influence the breakage of tolerance to IFNβ 
therapy. This is supported by a study by Weber et al. who identified one non-HLA SNP 
to be significantly associated with the anti-IFNβ antibody titers in MS patients treated 
with IFNβ. In addition, genetic polymorphisms in the genes encoding IL-10 and TNF-α 
have shown association to the development of anti-factor VIII antibodies, i.e. inhibitors, 
in hemophilia patients [170-172]. The functional analyses of these polymorphisms 
revealed that inhibitor development was more frequent in patients with production of 
high-TNF-α/high-IL-10 levels [170]. A recently published study describe that there are 
genome wide differences in gene expression between HLA-DRB1*15:01 positive and 
HLA-DRB1*15:01 negative MS patients [173]. Among the ~1200 exons identified to 
be differentially expressed between these two MS groups were genes known to be 
involved in distinct immune signaling pathways such as IL-4 and IL-17 signaling. 
Whether these differences between HLA-DRB1*15:01 carriers and non-carrier could 
influence our findings in study IV would be interesting to investigate. 
  
Cigarette smoking has been confirmed to be an environmental/life-style factor that 
increases the susceptibility to develop MS [54-56], and there is also a possible 
correlation between smoking and disease progression [174,175]. Interestingly; smoking 
has also been shown to influence the risk for MS patients to develop ADA against both 
IFNβ [136,137] and natalizumab [176]. These findings suggest that the lung is an 
immune-competent organ, which not only impact disease susceptibility but also 
influences the response to therapy. Thus, there is a potential benefit of smoking 
cessation in MS patients planning to initiate treatment with BPs. The importance of 
environmental/life-style factors for ADA development has only begun to be explored, 
and it would also be of interest to study whether the immune modulating effects of 
sunlight and/or vitamin D [177] can have a protective effect on the development of 
ADA responses. 
 
NAbs against IFNβ can persist for several years after stopping treatment [178,179]. 
Furthermore, NAbs against recombinant IFNβ therapy cross-react with and neutralize 
the effect of endogenously produced IFNβ in vitro [180]. Thus, in patients with 
persistent NAbs the endogenous IFNβ response may be hampered, possibly making 
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these patients more susceptible to viral infections. Although this may not lead to severe 
consequences in MS patients, the persistence of ADA in patients receiving replacement 
therapy with factor VIII or hormones could be life-threatening. There is thus a need to 
find ways to efficiently deplete the ADA response once they have developed to be able 
to reduce the consequences for treated patients. This could be done with immune 
tolerance induction (ITI) therapy or with therapies targeting B cell responses, e.g. 
rituximab. These are alternatives that need to be investigated further.    
 
In conclusion, since the introduction of BPs there have been major improvements in the 
treatments of several different diseases, including MS. To make these treatments more 
efficient and safer for the patients it is important that we increase our understanding of 
the immunological mechanisms leading to ADA responses, and how genetic and 
environmental factors may influence the immunogenicity of recombinant human 
proteins. By taking the development of ADAs into consideration and by including 
ADA analysis in routine practice the ineffective treatment of patients can be avoided, 
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